

**ASX ANNOUNCEMENT**

**APPOINTMENT OF DIRECTOR**

**SYDNEY, Wednesday, 19 September 2012: Cellmid Limited (ASX: CDY)** today appointed Mr Martin Rogers as a non-executive director of the Company.

Martin Rogers is the former CEO and current non-executive director of Prima BioMed Ltd. He has chemical engineering and science degrees and has a depth of experience in incubating companies and publicly listed organisations.

Mr Rogers has experience in all aspects of financial, strategic and operational management and has raised over \$100m in equity. He has been both an investor and senior executive in a private funded advisory business in the science and biotechnology sectors, where he was instrumental in significantly increasing the value of those investments.

Mr Rogers also holds a number of not-for-profit roles and is on the management committee of the National Breast Cancer Foundation and a Council Member at the University of Sydney Physics Foundation and International Science School. Mr Rogers is currently serving as Deputy Chairman of Consegna Group Ltd.

"Martin's outstanding track record in biotechnology and his knowledge of and enthusiasm for the midkine and Advangen portfolio makes him an ideal candidate to join our board" said Chairman Dr David King. "His appointment means that we now have a well-rounded and strong board with experience in biotechnology strategy, finance, operations and business development" he added.

End

Contact:

David King, Chairman

T +612 9299 0311

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development programme is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.